IFN-λ cancer immunotherapy: New kid on the block

Ahmed Lasfar; Helen Gogas; Andrew Zloza; Howard L. Kaufman; John M. Kirkwood

doi:10.2217/imt-2015-0021

IFN-λ cancer immunotherapy: New kid on the block

Ahmed Lasfar, Helen Gogas, Andrew Zloza, Howard L. Kaufman, John M. Kirkwood

Research output: Contribution to journal › Review article › peer-review

Abstract

Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this review, we discuss the current landscape of IFN-α use in oncology and describe the biologic characteristics of IFN-λ. IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses. IFN-λ has also demonstrated therapeutic benefit in murine cancer models. IFN-λ may be used in clinic as a single agent or in combination with other immunotherapy agents, such as immune checkpoint inhibitors. Further clinical trials will be needed to fully elucidate the potential of this novel agent in oncology.

Original language	English (US)
Pages (from-to)	877-888
Number of pages	12
Journal	Immunotherapy
Volume	8
Issue number	8
DOIs	https://doi.org/10.2217/imt-2015-0021
State	Published - Jul 2016
Externally published	Yes

Keywords

IFN therapy
IFN-α/λ combination
IFN-λ
immune check point inhibitors

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2015-0021

Cite this

@article{f3aec2e2444644819912036ac436355a,

title = "IFN-λ cancer immunotherapy: New kid on the block",

abstract = "Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this review, we discuss the current landscape of IFN-α use in oncology and describe the biologic characteristics of IFN-λ. IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses. IFN-λ has also demonstrated therapeutic benefit in murine cancer models. IFN-λ may be used in clinic as a single agent or in combination with other immunotherapy agents, such as immune checkpoint inhibitors. Further clinical trials will be needed to fully elucidate the potential of this novel agent in oncology.",

keywords = "IFN therapy, IFN-α/λ combination, IFN-λ, immune check point inhibitors",

author = "Ahmed Lasfar and Helen Gogas and Andrew Zloza and Kaufman, {Howard L.} and Kirkwood, {John M.}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = jul,

doi = "10.2217/imt-2015-0021",

language = "English (US)",

volume = "8",

pages = "877--888",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "8",

}

TY - JOUR

T1 - IFN-λ cancer immunotherapy

T2 - New kid on the block

AU - Lasfar, Ahmed

AU - Gogas, Helen

AU - Zloza, Andrew

AU - Kaufman, Howard L.

AU - Kirkwood, John M.

PY - 2016/7

Y1 - 2016/7

N2 - Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this review, we discuss the current landscape of IFN-α use in oncology and describe the biologic characteristics of IFN-λ. IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses. IFN-λ has also demonstrated therapeutic benefit in murine cancer models. IFN-λ may be used in clinic as a single agent or in combination with other immunotherapy agents, such as immune checkpoint inhibitors. Further clinical trials will be needed to fully elucidate the potential of this novel agent in oncology.

AB - Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this review, we discuss the current landscape of IFN-α use in oncology and describe the biologic characteristics of IFN-λ. IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses. IFN-λ has also demonstrated therapeutic benefit in murine cancer models. IFN-λ may be used in clinic as a single agent or in combination with other immunotherapy agents, such as immune checkpoint inhibitors. Further clinical trials will be needed to fully elucidate the potential of this novel agent in oncology.

KW - IFN therapy

KW - IFN-α/λ combination

KW - IFN-λ

KW - immune check point inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84978954013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978954013&partnerID=8YFLogxK

U2 - 10.2217/imt-2015-0021

DO - 10.2217/imt-2015-0021

M3 - Review article

C2 - 27381684

AN - SCOPUS:84978954013

SN - 1750-743X

VL - 8

SP - 877

EP - 888

JO - Immunotherapy

JF - Immunotherapy

IS - 8

ER -

IFN-λ cancer immunotherapy: New kid on the block

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this